Apotex Pty Ltd (ACN 096 916 148) v Les Laboratoires Servier
[2008] FCA 1466
At a glance
Source factsCourt
Federal Court of Australia
Decision date
2008-09-30
Before
Bennett J
Source
Original judgment source is linked above.
Judgment (10 paragraphs)
- By 4:00 pm on 3 October 2008: a) Each party inform the Court whether it accepts or disputes that the respondent's waiver of privilege applies to all documents in the notice to produce and, if not, to which documents it does not apply. b) The parties propose any necessary directions for the conduct of the matter prior to the resumed hearing on 22 October 2008. Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules. IN THE FEDERAL COURT OF AUSTRALIA
REASONS FOR JUDGMENT 1 By notice of motion in these proceedings, Les Laboratoires Servier ('Servier') seeks to amend its Australian Patent No 2001276418 ('the Alpha Crystalline Patent') pursuant to s 105 of the Patents Act 1990 (Cth). In support of that application, Servier relies on the affidavits of Mr Richard Hamer, the partner of Allens Arthur Robinson who has the conduct of the proceedings on behalf of Servier. Mr Hamer states that he is aware of the facts deposed to in his affidavits from his own involvement in the proceedings except for certain information obtained from the patent records. 2 Apotex Pty Ltd ('Apotex') has served a notice to produce on Servier. Apotex seeks documents, for example, those recording or referring to Mr Hamer's views as expressed in the affidavits, including his views that amendments to the Alpha Crystalline Patent were necessary. Apotex also requires discovery of, for example, instructions from Servier to Allens Arthur Robinson, as referred to in the affidavits. 3 Servier claims privilege over those documents. Apotex contends that Servier has waived any such privilege. 4 The specific paragraphs of Mr Hamer's affidavits that are the subject of the notice to produce include: · [7] of the first affidavit: Following the receipt of instructions and between December 2006 and early February 2007, I reviewed the Alpha Crystalline Patent and formed the view that the specifications disclosed matter which could be the basis of additional claims. In particular, that matter related to the crystal habit and filterability of the crystals described in the specification. · [6] and [8] of the second affidavit: 6. My review of the Innovation Patent [Innovation patent application number AU2006101079] caused me to consider the scope of the claims of the Alpha Crystalline Patent. I realised that subject matter was described in the Alpha Crystalline Patent, which was not the subject of relevant claims. In particular, the Alpha Crystalline Patent, at page 2 describes the fact that: "…the Applicant has now found that a particular salt of perindopril, the tert-butylamine salt, can be obtained in a well-defined, perfectly reproducible crystalline form that especially exhibits valuable characteristics of filtration, drying and ease of formulation." ... 8. In that context, it appeared to me that there was basis to amend the Alpha Crystalline Patent to include claims directed to the needle crystal habit, which were not limited by the matters specified in claim 2. Because more than 3 months had passed since the patent application had been accepted, however, new claims would have to be within the scope of existing claims of the patent before amendment. 5 In other parts of the second affidavit, Mr Hamer refers to his views regarding an opposition to the Alpha Crystalline Patent ('the Lupin opposition') and infringement of that Patent by Apotex. These paragraphs of Mr Hamer's second affidavit are also referred to in the notice to produce.